U.S. Markets open in 3 hrs 25 mins

Biofrontera AG (B8F.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
3.667-0.030 (-0.811%)
As of 11:48AM CEST. Market open.

Biofrontera AG

Hemmelrather Weg 201
Leverkusen 51377
Germany
49 214 87 63 20
http://www.biofrontera.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees94

Key Executives

NameTitlePayExercisedAge
Prof. Hermann Lübbert Ph.D.Co-Founder, Chairman of Management Board and Chief Exec. Officer435kN/A61
Mr. Thomas SchafferChief Financial Officer and Member of Management Board276kN/AN/A
Mr. Christoph DünwaldChief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board242kN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Corporate Governance

Biofrontera AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.